nodes	percent_of_prediction	percent_of_DWPC	metapath
Norethindrone—CYP3A4—Temozolomide—brain cancer	0.171	0.342	CbGbCtD
Norethindrone—CYP3A4—Lomustine—brain cancer	0.146	0.291	CbGbCtD
Norethindrone—CYP3A5—Etoposide—brain cancer	0.0903	0.18	CbGbCtD
Norethindrone—ABCB1—Etoposide—brain cancer	0.0587	0.117	CbGbCtD
Norethindrone—CYP3A4—Etoposide—brain cancer	0.0352	0.0702	CbGbCtD
Norethindrone—Infertility—Procarbazine—brain cancer	0.0228	0.0532	CcSEcCtD
Norethindrone—Blindness—Lomustine—brain cancer	0.0169	0.0395	CcSEcCtD
Norethindrone—Infertility—Carmustine—brain cancer	0.0143	0.0333	CcSEcCtD
Norethindrone—Infertility—Temozolomide—brain cancer	0.0138	0.0322	CcSEcCtD
Norethindrone—Optic neuritis—Procarbazine—brain cancer	0.00968	0.0226	CcSEcCtD
Norethindrone—Thrombosis—Procarbazine—brain cancer	0.00841	0.0196	CcSEcCtD
Norethindrone—Gastrointestinal symptom NOS—Hydroxyurea—brain cancer	0.00784	0.0183	CcSEcCtD
Norethindrone—Neoplasm malignant—Procarbazine—brain cancer	0.00697	0.0163	CcSEcCtD
Norethindrone—Digestion impaired—Hydroxyurea—brain cancer	0.00689	0.0161	CcSEcCtD
Norethindrone—Amenorrhoea—Procarbazine—brain cancer	0.00678	0.0158	CcSEcCtD
Norethindrone—Cerebral haemorrhage—Carmustine—brain cancer	0.00673	0.0157	CcSEcCtD
Norethindrone—Cerebral haemorrhage—Temozolomide—brain cancer	0.0065	0.0152	CcSEcCtD
Norethindrone—Deep vein thrombosis—Temozolomide—brain cancer	0.00592	0.0138	CcSEcCtD
Norethindrone—Embolism—Temozolomide—brain cancer	0.00561	0.0131	CcSEcCtD
Norethindrone—Digestion impaired—Temozolomide—brain cancer	0.00538	0.0126	CcSEcCtD
Norethindrone—Tenderness—Hydroxyurea—brain cancer	0.00528	0.0123	CcSEcCtD
Norethindrone—Thrombosis—Carmustine—brain cancer	0.00526	0.0123	CcSEcCtD
Norethindrone—Amenorrhoea—Hydroxyurea—brain cancer	0.00524	0.0122	CcSEcCtD
Norethindrone—Renal failure—Lomustine—brain cancer	0.00516	0.012	CcSEcCtD
Norethindrone—Photosensitivity—Procarbazine—brain cancer	0.00492	0.0115	CcSEcCtD
Norethindrone—Menorrhagia—Temozolomide—brain cancer	0.00486	0.0114	CcSEcCtD
Norethindrone—Vaginal haemorrhage—Temozolomide—brain cancer	0.00486	0.0114	CcSEcCtD
Norethindrone—Haemoglobin—Lomustine—brain cancer	0.00473	0.011	CcSEcCtD
Norethindrone—Haemorrhage—Lomustine—brain cancer	0.00471	0.011	CcSEcCtD
Norethindrone—Optic neuritis—Etoposide—brain cancer	0.00468	0.0109	CcSEcCtD
Norethindrone—Purpura—Procarbazine—brain cancer	0.00448	0.0105	CcSEcCtD
Norethindrone—Mestranol—CYP2C9—brain cancer	0.00441	0.47	CrCbGaD
Norethindrone—Alopecia—Lomustine—brain cancer	0.00416	0.00971	CcSEcCtD
Norethindrone—Breast pain—Temozolomide—brain cancer	0.00413	0.00963	CcSEcCtD
Norethindrone—Amenorrhoea—Temozolomide—brain cancer	0.0041	0.00956	CcSEcCtD
Norethindrone—Pulmonary embolism—Carmustine—brain cancer	0.00372	0.00869	CcSEcCtD
Norethindrone—Pulmonary embolism—Temozolomide—brain cancer	0.0036	0.0084	CcSEcCtD
Norethindrone—Photosensitivity reaction—Procarbazine—brain cancer	0.00341	0.00796	CcSEcCtD
Norethindrone—Drowsiness—Procarbazine—brain cancer	0.00333	0.00777	CcSEcCtD
Norethindrone—CYP2C19—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP2C9—brain cancer	0.00322	0.0527	CbGpPWpGaD
Norethindrone—Thrombophlebitis—Carmustine—brain cancer	0.00312	0.00729	CcSEcCtD
Norethindrone—Breast disorder—Hydroxyurea—brain cancer	0.00302	0.00705	CcSEcCtD
Norethindrone—Thrombophlebitis—Temozolomide—brain cancer	0.00302	0.00705	CcSEcCtD
Norethindrone—Haemoglobin—Procarbazine—brain cancer	0.003	0.00701	CcSEcCtD
Norethindrone—Haemorrhage—Procarbazine—brain cancer	0.00299	0.00698	CcSEcCtD
Norethindrone—CYP2C19—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP2C9—brain cancer	0.00293	0.048	CbGpPWpGaD
Norethindrone—CYP3A7—Xenobiotics—CYP2C9—brain cancer	0.00277	0.0453	CbGpPWpGaD
Norethindrone—Purpura—Temozolomide—brain cancer	0.00271	0.00633	CcSEcCtD
Norethindrone—Ethinyl Estradiol—ESR2—brain cancer	0.00268	0.285	CrCbGaD
Norethindrone—Alopecia—Procarbazine—brain cancer	0.00264	0.00617	CcSEcCtD
Norethindrone—Weight increased—Hydroxyurea—brain cancer	0.00263	0.00614	CcSEcCtD
Norethindrone—Drowsiness—Hydroxyurea—brain cancer	0.00258	0.00602	CcSEcCtD
Norethindrone—Affect lability—Temozolomide—brain cancer	0.00257	0.006	CcSEcCtD
Norethindrone—Tension—Procarbazine—brain cancer	0.00255	0.00596	CcSEcCtD
Norethindrone—Nervousness—Procarbazine—brain cancer	0.00253	0.0059	CcSEcCtD
Norethindrone—CYP2C19—CYP2E1 reactions—CYP2C9—brain cancer	0.0025	0.0409	CbGpPWpGaD
Norethindrone—Mood swings—Temozolomide—brain cancer	0.00248	0.00578	CcSEcCtD
Norethindrone—Hepatobiliary disease—Hydroxyurea—brain cancer	0.00244	0.00569	CcSEcCtD
Norethindrone—Breast disorder—Temozolomide—brain cancer	0.00236	0.00551	CcSEcCtD
Norethindrone—Haemoglobin—Hydroxyurea—brain cancer	0.00233	0.00543	CcSEcCtD
Norethindrone—Haemorrhage—Hydroxyurea—brain cancer	0.00231	0.0054	CcSEcCtD
Norethindrone—Abdominal distension—Temozolomide—brain cancer	0.00227	0.00531	CcSEcCtD
Norethindrone—Convulsion—Procarbazine—brain cancer	0.00225	0.00526	CcSEcCtD
Norethindrone—Anaphylactoid reaction—Etoposide—brain cancer	0.00216	0.00504	CcSEcCtD
Norethindrone—Vomiting—Lomustine—brain cancer	0.00213	0.00496	CcSEcCtD
Norethindrone—Oedema—Procarbazine—brain cancer	0.00212	0.00496	CcSEcCtD
Norethindrone—PGR—Nuclear signaling by ERBB4—GFAP—brain cancer	0.00209	0.0341	CbGpPWpGaD
Norethindrone—Depression—Carmustine—brain cancer	0.00208	0.00485	CcSEcCtD
Norethindrone—Photosensitivity reaction—Temozolomide—brain cancer	0.00206	0.00481	CcSEcCtD
Norethindrone—Weight increased—Temozolomide—brain cancer	0.00206	0.0048	CcSEcCtD
Norethindrone—Renal failure—Carmustine—brain cancer	0.00205	0.00478	CcSEcCtD
Norethindrone—Alopecia—Hydroxyurea—brain cancer	0.00204	0.00477	CcSEcCtD
Norethindrone—Depression—Temozolomide—brain cancer	0.00201	0.00469	CcSEcCtD
Norethindrone—CYP3A5—Xenobiotics—CYP2C9—brain cancer	0.002	0.0328	CbGpPWpGaD
Norethindrone—Nausea—Lomustine—brain cancer	0.00199	0.00464	CcSEcCtD
Norethindrone—CYP3A5—Tamoxifen metabolism—CYP2C9—brain cancer	0.00193	0.0315	CbGpPWpGaD
Norethindrone—Insomnia—Procarbazine—brain cancer	0.00192	0.00448	CcSEcCtD
Norethindrone—Hepatobiliary disease—Temozolomide—brain cancer	0.0019	0.00444	CcSEcCtD
Norethindrone—Somnolence—Procarbazine—brain cancer	0.00189	0.00441	CcSEcCtD
Norethindrone—Haemoglobin—Carmustine—brain cancer	0.00188	0.00439	CcSEcCtD
Norethindrone—Haemorrhage—Carmustine—brain cancer	0.00187	0.00437	CcSEcCtD
Norethindrone—Connective tissue disorder—Carmustine—brain cancer	0.00184	0.00429	CcSEcCtD
Norethindrone—Fatigue—Procarbazine—brain cancer	0.00183	0.00427	CcSEcCtD
Norethindrone—Haemoglobin—Temozolomide—brain cancer	0.00182	0.00424	CcSEcCtD
Norethindrone—Haemorrhage—Temozolomide—brain cancer	0.00181	0.00422	CcSEcCtD
Norethindrone—Hepatitis—Temozolomide—brain cancer	0.00181	0.00422	CcSEcCtD
Norethindrone—Connective tissue disorder—Temozolomide—brain cancer	0.00178	0.00415	CcSEcCtD
Norethindrone—Convulsion—Hydroxyurea—brain cancer	0.00175	0.00407	CcSEcCtD
Norethindrone—Gastrointestinal pain—Procarbazine—brain cancer	0.00174	0.00405	CcSEcCtD
Norethindrone—Erythema multiforme—Temozolomide—brain cancer	0.00171	0.00399	CcSEcCtD
Norethindrone—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—brain cancer	0.0017	0.00397	CcSEcCtD
Norethindrone—Urticaria—Procarbazine—brain cancer	0.00169	0.00394	CcSEcCtD
Norethindrone—Abdominal pain—Procarbazine—brain cancer	0.00168	0.00392	CcSEcCtD
Norethindrone—Alopecia—Carmustine—brain cancer	0.00165	0.00386	CcSEcCtD
Norethindrone—Oedema—Hydroxyurea—brain cancer	0.00164	0.00384	CcSEcCtD
Norethindrone—Mental disorder—Carmustine—brain cancer	0.00164	0.00382	CcSEcCtD
Norethindrone—Immune system disorder—Temozolomide—brain cancer	0.00163	0.00381	CcSEcCtD
Norethindrone—Alopecia—Temozolomide—brain cancer	0.0016	0.00373	CcSEcCtD
Norethindrone—Skin disorder—Hydroxyurea—brain cancer	0.0016	0.00373	CcSEcCtD
Norethindrone—Acute coronary syndrome—Etoposide—brain cancer	0.00159	0.00371	CcSEcCtD
Norethindrone—Renal failure—Etoposide—brain cancer	0.00158	0.0037	CcSEcCtD
Norethindrone—Mental disorder—Temozolomide—brain cancer	0.00158	0.0037	CcSEcCtD
Norethindrone—Myocardial infarction—Etoposide—brain cancer	0.00158	0.00369	CcSEcCtD
Norethindrone—Hypersensitivity—Procarbazine—brain cancer	0.00156	0.00365	CcSEcCtD
Norethindrone—CYP2C19—Xenobiotics—CYP2C9—brain cancer	0.00155	0.0253	CbGpPWpGaD
Norethindrone—PGR—Ovarian Infertility Genes—ESR2—brain cancer	0.00155	0.0253	CbGpPWpGaD
Norethindrone—Asthenia—Procarbazine—brain cancer	0.00152	0.00356	CcSEcCtD
Norethindrone—Hepatobiliary disease—Etoposide—brain cancer	0.00152	0.00356	CcSEcCtD
Norethindrone—Pruritus—Procarbazine—brain cancer	0.0015	0.00351	CcSEcCtD
Norethindrone—CYP2C19—Tamoxifen metabolism—CYP2C9—brain cancer	0.00149	0.0244	CbGpPWpGaD
Norethindrone—Somnolence—Hydroxyurea—brain cancer	0.00146	0.00341	CcSEcCtD
Norethindrone—Dyspepsia—Hydroxyurea—brain cancer	0.00145	0.00338	CcSEcCtD
Norethindrone—Gastrointestinal disorder—Hydroxyurea—brain cancer	0.00142	0.00331	CcSEcCtD
Norethindrone—Fatigue—Hydroxyurea—brain cancer	0.00142	0.00331	CcSEcCtD
Norethindrone—Convulsion—Carmustine—brain cancer	0.00141	0.00329	CcSEcCtD
Norethindrone—Dizziness—Procarbazine—brain cancer	0.0014	0.00328	CcSEcCtD
Norethindrone—CYP3A5—Constitutive Androstane Receptor Pathway—CYP2C9—brain cancer	0.00138	0.0225	CbGpPWpGaD
Norethindrone—Erythema multiforme—Etoposide—brain cancer	0.00137	0.00319	CcSEcCtD
Norethindrone—Convulsion—Temozolomide—brain cancer	0.00136	0.00318	CcSEcCtD
Norethindrone—Vomiting—Procarbazine—brain cancer	0.00135	0.00315	CcSEcCtD
Norethindrone—PGR—Nuclear Receptors—ESR2—brain cancer	0.00135	0.022	CbGpPWpGaD
Norethindrone—Rash—Procarbazine—brain cancer	0.00134	0.00313	CcSEcCtD
Norethindrone—Dermatitis—Procarbazine—brain cancer	0.00134	0.00312	CcSEcCtD
Norethindrone—Headache—Procarbazine—brain cancer	0.00133	0.00311	CcSEcCtD
Norethindrone—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—brain cancer	0.00133	0.00311	CcSEcCtD
Norethindrone—Oedema—Carmustine—brain cancer	0.00133	0.0031	CcSEcCtD
Norethindrone—Immune system disorder—Etoposide—brain cancer	0.00131	0.00305	CcSEcCtD
Norethindrone—Anaphylactic shock—Temozolomide—brain cancer	0.00128	0.003	CcSEcCtD
Norethindrone—Oedema—Temozolomide—brain cancer	0.00128	0.003	CcSEcCtD
Norethindrone—Alopecia—Etoposide—brain cancer	0.00128	0.00298	CcSEcCtD
Norethindrone—Nausea—Procarbazine—brain cancer	0.00126	0.00294	CcSEcCtD
Norethindrone—Skin disorder—Temozolomide—brain cancer	0.00125	0.00291	CcSEcCtD
Norethindrone—Hypersensitivity—Hydroxyurea—brain cancer	0.00121	0.00283	CcSEcCtD
Norethindrone—Insomnia—Carmustine—brain cancer	0.0012	0.00281	CcSEcCtD
Norethindrone—Somnolence—Carmustine—brain cancer	0.00118	0.00276	CcSEcCtD
Norethindrone—Asthenia—Hydroxyurea—brain cancer	0.00118	0.00275	CcSEcCtD
Norethindrone—Progesterone—CYP2C9—brain cancer	0.00118	0.126	CrCbGaD
Norethindrone—Insomnia—Temozolomide—brain cancer	0.00116	0.00271	CcSEcCtD
Norethindrone—CYP3A7—Cytochrome P450 - arranged by substrate type—CYP2C9—brain cancer	0.00115	0.0188	CbGpPWpGaD
Norethindrone—Gastrointestinal disorder—Carmustine—brain cancer	0.00115	0.00268	CcSEcCtD
Norethindrone—Somnolence—Temozolomide—brain cancer	0.00114	0.00266	CcSEcCtD
Norethindrone—CYP3A7—Oxidation by Cytochrome P450—CYP2C9—brain cancer	0.00114	0.0186	CbGpPWpGaD
Norethindrone—Dyspepsia—Temozolomide—brain cancer	0.00113	0.00264	CcSEcCtD
Norethindrone—Testosterone—CYP2C9—brain cancer	0.00111	0.119	CrCbGaD
Norethindrone—Gastrointestinal disorder—Temozolomide—brain cancer	0.00111	0.00259	CcSEcCtD
Norethindrone—Fatigue—Temozolomide—brain cancer	0.00111	0.00258	CcSEcCtD
Norethindrone—Convulsion—Etoposide—brain cancer	0.00109	0.00255	CcSEcCtD
Norethindrone—Dizziness—Hydroxyurea—brain cancer	0.00109	0.00254	CcSEcCtD
Norethindrone—Gastrointestinal pain—Carmustine—brain cancer	0.00109	0.00254	CcSEcCtD
Norethindrone—Unspecified disorder of skin and subcutaneous tissue—Etoposide—brain cancer	0.00106	0.00248	CcSEcCtD
Norethindrone—PGR—Nuclear Receptor transcription pathway—ESR2—brain cancer	0.00106	0.0174	CbGpPWpGaD
Norethindrone—CYP2C19—Constitutive Androstane Receptor Pathway—CYP2C9—brain cancer	0.00106	0.0174	CbGpPWpGaD
Norethindrone—Abdominal pain—Carmustine—brain cancer	0.00105	0.00245	CcSEcCtD
Norethindrone—Gastrointestinal pain—Temozolomide—brain cancer	0.00105	0.00245	CcSEcCtD
Norethindrone—Vomiting—Hydroxyurea—brain cancer	0.00105	0.00244	CcSEcCtD
Norethindrone—ABCB1—Constitutive Androstane Receptor Pathway—CYP2C9—brain cancer	0.00104	0.017	CbGpPWpGaD
Norethindrone—Rash—Hydroxyurea—brain cancer	0.00104	0.00242	CcSEcCtD
Norethindrone—Dermatitis—Hydroxyurea—brain cancer	0.00104	0.00242	CcSEcCtD
Norethindrone—Headache—Hydroxyurea—brain cancer	0.00103	0.0024	CcSEcCtD
Norethindrone—Anaphylactic shock—Etoposide—brain cancer	0.00103	0.0024	CcSEcCtD
Norethindrone—Urticaria—Temozolomide—brain cancer	0.00102	0.00238	CcSEcCtD
Norethindrone—Abdominal pain—Temozolomide—brain cancer	0.00102	0.00237	CcSEcCtD
Norethindrone—Skin disorder—Etoposide—brain cancer	0.000998	0.00233	CcSEcCtD
Norethindrone—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP2C9—brain cancer	0.000989	0.0162	CbGpPWpGaD
Norethindrone—Hypersensitivity—Carmustine—brain cancer	0.000979	0.00229	CcSEcCtD
Norethindrone—Nausea—Hydroxyurea—brain cancer	0.000976	0.00228	CcSEcCtD
Norethindrone—Asthenia—Carmustine—brain cancer	0.000953	0.00223	CcSEcCtD
Norethindrone—Hypersensitivity—Temozolomide—brain cancer	0.000946	0.00221	CcSEcCtD
Norethindrone—PGR—Ovarian Infertility Genes—CDK4—brain cancer	0.000941	0.0154	CbGpPWpGaD
Norethindrone—CYP3A7—Phase 1 - Functionalization of compounds—CYP2C9—brain cancer	0.000933	0.0153	CbGpPWpGaD
Norethindrone—CYP3A4—Xenobiotics—CYP2C9—brain cancer	0.000931	0.0152	CbGpPWpGaD
Norethindrone—Asthenia—Temozolomide—brain cancer	0.000921	0.00215	CcSEcCtD
Norethindrone—Somnolence—Etoposide—brain cancer	0.000914	0.00213	CcSEcCtD
Norethindrone—Pruritus—Temozolomide—brain cancer	0.000909	0.00212	CcSEcCtD
Norethindrone—CYP3A4—Tamoxifen metabolism—CYP2C9—brain cancer	0.000896	0.0147	CbGpPWpGaD
Norethindrone—PGR—Validated nuclear estrogen receptor alpha network—ESR2—brain cancer	0.000888	0.0145	CbGpPWpGaD
Norethindrone—Gastrointestinal disorder—Etoposide—brain cancer	0.000887	0.00207	CcSEcCtD
Norethindrone—Fatigue—Etoposide—brain cancer	0.000886	0.00207	CcSEcCtD
Norethindrone—Dizziness—Carmustine—brain cancer	0.000879	0.00205	CcSEcCtD
Norethindrone—Dizziness—Temozolomide—brain cancer	0.000849	0.00198	CcSEcCtD
Norethindrone—Vomiting—Carmustine—brain cancer	0.000845	0.00197	CcSEcCtD
Norethindrone—Gastrointestinal pain—Etoposide—brain cancer	0.00084	0.00196	CcSEcCtD
Norethindrone—Rash—Carmustine—brain cancer	0.000838	0.00196	CcSEcCtD
Norethindrone—Dermatitis—Carmustine—brain cancer	0.000837	0.00195	CcSEcCtD
Norethindrone—Headache—Carmustine—brain cancer	0.000832	0.00194	CcSEcCtD
Norethindrone—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP2C9—brain cancer	0.000832	0.0136	CbGpPWpGaD
Norethindrone—CYP3A5—Oxidation by Cytochrome P450—CYP2C9—brain cancer	0.000821	0.0134	CbGpPWpGaD
Norethindrone—Vomiting—Temozolomide—brain cancer	0.000816	0.00191	CcSEcCtD
Norethindrone—Urticaria—Etoposide—brain cancer	0.000816	0.00191	CcSEcCtD
Norethindrone—Abdominal pain—Etoposide—brain cancer	0.000812	0.0019	CcSEcCtD
Norethindrone—Rash—Temozolomide—brain cancer	0.00081	0.00189	CcSEcCtD
Norethindrone—Dermatitis—Temozolomide—brain cancer	0.000809	0.00189	CcSEcCtD
Norethindrone—Headache—Temozolomide—brain cancer	0.000804	0.00188	CcSEcCtD
Norethindrone—Nausea—Carmustine—brain cancer	0.000789	0.00184	CcSEcCtD
Norethindrone—Nausea—Temozolomide—brain cancer	0.000763	0.00178	CcSEcCtD
Norethindrone—Hypersensitivity—Etoposide—brain cancer	0.000757	0.00177	CcSEcCtD
Norethindrone—CYP2C19—Arachidonic acid metabolism—CYP2C9—brain cancer	0.000744	0.0122	CbGpPWpGaD
Norethindrone—Asthenia—Etoposide—brain cancer	0.000737	0.00172	CcSEcCtD
Norethindrone—Pruritus—Etoposide—brain cancer	0.000727	0.0017	CcSEcCtD
Norethindrone—CYP3A5—Irinotecan Pathway—APC—brain cancer	0.000706	0.0116	CbGpPWpGaD
Norethindrone—PGR—Signaling by ERBB4—GFAP—brain cancer	0.000703	0.0115	CbGpPWpGaD
Norethindrone—Dizziness—Etoposide—brain cancer	0.00068	0.00159	CcSEcCtD
Norethindrone—CYP3A5—Phase 1 - Functionalization of compounds—CYP2C9—brain cancer	0.000674	0.011	CbGpPWpGaD
Norethindrone—Vomiting—Etoposide—brain cancer	0.000653	0.00153	CcSEcCtD
Norethindrone—Rash—Etoposide—brain cancer	0.000648	0.00151	CcSEcCtD
Norethindrone—Dermatitis—Etoposide—brain cancer	0.000647	0.00151	CcSEcCtD
Norethindrone—Headache—Etoposide—brain cancer	0.000644	0.0015	CcSEcCtD
Norethindrone—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP2C9—brain cancer	0.000643	0.0105	CbGpPWpGaD
Norethindrone—CYP3A4—Constitutive Androstane Receptor Pathway—CYP2C9—brain cancer	0.000639	0.0105	CbGpPWpGaD
Norethindrone—CYP2C19—Oxidation by Cytochrome P450—CYP2C9—brain cancer	0.000635	0.0104	CbGpPWpGaD
Norethindrone—PGR—Validated nuclear estrogen receptor alpha network—PCNA—brain cancer	0.000625	0.0102	CbGpPWpGaD
Norethindrone—Nausea—Etoposide—brain cancer	0.00061	0.00142	CcSEcCtD
Norethindrone—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP2C9—brain cancer	0.000609	0.00997	CbGpPWpGaD
Norethindrone—CYP2C19—Phase 1 - Functionalization of compounds—CYP2C9—brain cancer	0.000521	0.00853	CbGpPWpGaD
Norethindrone—CYP3A7—Biological oxidations—CYP2C9—brain cancer	0.000495	0.00811	CbGpPWpGaD
Norethindrone—CYP3A7—Metapathway biotransformation—CYP2C9—brain cancer	0.000489	0.008	CbGpPWpGaD
Norethindrone—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—SKP2—brain cancer	0.000404	0.00662	CbGpPWpGaD
Norethindrone—PGR—Signaling by ERBB4—VAV1—brain cancer	0.000401	0.00656	CbGpPWpGaD
Norethindrone—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2C9—brain cancer	0.000387	0.00633	CbGpPWpGaD
Norethindrone—CYP3A4—Oxidation by Cytochrome P450—CYP2C9—brain cancer	0.000382	0.00624	CbGpPWpGaD
Norethindrone—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—CDK6—brain cancer	0.00036	0.0059	CbGpPWpGaD
Norethindrone—CYP3A5—Biological oxidations—CYP2C9—brain cancer	0.000358	0.00586	CbGpPWpGaD
Norethindrone—CYP3A5—Metapathway biotransformation—CYP2C9—brain cancer	0.000353	0.00578	CbGpPWpGaD
Norethindrone—PGR—Validated nuclear estrogen receptor alpha network—CCND1—brain cancer	0.000349	0.00571	CbGpPWpGaD
Norethindrone—PGR—Signaling by ERBB4—PDGFRA—brain cancer	0.000329	0.00538	CbGpPWpGaD
Norethindrone—CYP3A4—Irinotecan Pathway—APC—brain cancer	0.000328	0.00537	CbGpPWpGaD
Norethindrone—ALB—Platelet activation, signaling and aggregation—MPL—brain cancer	0.000318	0.0052	CbGpPWpGaD
Norethindrone—CYP3A4—Phase 1 - Functionalization of compounds—CYP2C9—brain cancer	0.000313	0.00513	CbGpPWpGaD
Norethindrone—ALB—Vitamin B12 Metabolism—SOD2—brain cancer	0.000292	0.00478	CbGpPWpGaD
Norethindrone—CYP3A4—Farnesoid X Receptor  Pathway—IRS2—brain cancer	0.000291	0.00477	CbGpPWpGaD
Norethindrone—PGR—Signaling by ERBB4—IRS2—brain cancer	0.000288	0.00472	CbGpPWpGaD
Norethindrone—PGR—Validated nuclear estrogen receptor alpha network—MYC—brain cancer	0.00028	0.00458	CbGpPWpGaD
Norethindrone—CYP2C19—Biological oxidations—CYP2C9—brain cancer	0.000277	0.00453	CbGpPWpGaD
Norethindrone—CYP2C19—Metapathway biotransformation—CYP2C9—brain cancer	0.000273	0.00447	CbGpPWpGaD
Norethindrone—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—PDGFRA—brain cancer	0.000252	0.00413	CbGpPWpGaD
Norethindrone—ALB—Folate Metabolism—SOD2—brain cancer	0.000238	0.00389	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—OR4C12—brain cancer	0.000217	0.00355	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—OR14C36—brain cancer	0.000217	0.00355	CbGpPWpGaD
Norethindrone—PGR—Signaling by ERBB4—ERBB2—brain cancer	0.000198	0.00324	CbGpPWpGaD
Norethindrone—ALB—Selenium Micronutrient Network—SOD2—brain cancer	0.000189	0.00309	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—DTX2—brain cancer	0.000184	0.00301	CbGpPWpGaD
Norethindrone—PGR—Generic Transcription Pathway—ESR2—brain cancer	0.000184	0.00301	CbGpPWpGaD
Norethindrone—PGR—Generic Transcription Pathway—NOTCH2—brain cancer	0.000174	0.00285	CbGpPWpGaD
Norethindrone—ABCB1—Allograft Rejection—PDGFRA—brain cancer	0.000172	0.00282	CbGpPWpGaD
Norethindrone—ALB—Vitamin B12 Metabolism—RELA—brain cancer	0.000169	0.00277	CbGpPWpGaD
Norethindrone—CYP3A4—Biological oxidations—CYP2C9—brain cancer	0.000167	0.00272	CbGpPWpGaD
Norethindrone—CYP3A4—Metapathway biotransformation—CYP2C9—brain cancer	0.000164	0.00269	CbGpPWpGaD
Norethindrone—ALB—Hemostasis—MPL—brain cancer	0.000164	0.00268	CbGpPWpGaD
Norethindrone—ALB—Hemostasis—S100A10—brain cancer	0.000157	0.00257	CbGpPWpGaD
Norethindrone—ABCB1—Integrated Pancreatic Cancer Pathway—SHH—brain cancer	0.000144	0.00235	CbGpPWpGaD
Norethindrone—ALB—Platelet activation, signaling and aggregation—TRPC6—brain cancer	0.000141	0.0023	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—PTCH2—brain cancer	0.00014	0.00228	CbGpPWpGaD
Norethindrone—ALB—Folate Metabolism—RELA—brain cancer	0.000138	0.00225	CbGpPWpGaD
Norethindrone—PGR—Signaling by ERBB4—EGFR—brain cancer	0.000137	0.00224	CbGpPWpGaD
Norethindrone—ABCB1—Integrated Pancreatic Cancer Pathway—SMO—brain cancer	0.000136	0.00223	CbGpPWpGaD
Norethindrone—ALB—Transmembrane transport of small molecules—S100A10—brain cancer	0.000136	0.00222	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—HES5—brain cancer	0.000135	0.00221	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—STRADA—brain cancer	0.000131	0.00215	CbGpPWpGaD
Norethindrone—ALB—Folate Metabolism—IL2—brain cancer	0.000124	0.00203	CbGpPWpGaD
Norethindrone—ABCB1—Transmembrane transport of small molecules—S100A10—brain cancer	0.000119	0.00195	CbGpPWpGaD
Norethindrone—ALB—Metabolism of lipids and lipoproteins—CYP2C9—brain cancer	0.000118	0.00194	CbGpPWpGaD
Norethindrone—ABCB1—Integrated Pancreatic Cancer Pathway—ESR2—brain cancer	0.000115	0.00188	CbGpPWpGaD
Norethindrone—ALB—Hemostasis—BSG—brain cancer	0.000111	0.00181	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—ABR—brain cancer	0.00011	0.00179	CbGpPWpGaD
Norethindrone—ALB—Selenium Micronutrient Network—RELA—brain cancer	0.000109	0.00179	CbGpPWpGaD
Norethindrone—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—brain cancer	0.000108	0.00176	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism of lipids and lipoproteins—CYP2C9—brain cancer	0.000106	0.00174	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—GLI2—brain cancer	0.000106	0.00173	CbGpPWpGaD
Norethindrone—ALB—Platelet activation, signaling and aggregation—VAV1—brain cancer	0.000105	0.00172	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—GLI1—brain cancer	9.95e-05	0.00163	CbGpPWpGaD
Norethindrone—PGR—Gene Expression—DNMT1—brain cancer	9.86e-05	0.00161	CbGpPWpGaD
Norethindrone—ABCB1—Integrated Pancreatic Cancer Pathway—BRCA2—brain cancer	9.44e-05	0.00154	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—SUFU—brain cancer	9.43e-05	0.00154	CbGpPWpGaD
Norethindrone—ABCB1—Allograft Rejection—IL2—brain cancer	9.4e-05	0.00154	CbGpPWpGaD
Norethindrone—ABCB1—Integrated Pancreatic Cancer Pathway—SIRT1—brain cancer	9.26e-05	0.00151	CbGpPWpGaD
Norethindrone—ABCB1—HIF-1-alpha transcription factor network—VEGFA—brain cancer	9.22e-05	0.00151	CbGpPWpGaD
Norethindrone—ABCB1—Integrated Pancreatic Cancer Pathway—CCNE1—brain cancer	9.14e-05	0.0015	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—GFAP—brain cancer	9.1e-05	0.00149	CbGpPWpGaD
Norethindrone—ALB—Platelet degranulation—VEGFA—brain cancer	9.02e-05	0.00148	CbGpPWpGaD
Norethindrone—PGR—Gene Expression—ESR2—brain cancer	8.85e-05	0.00145	CbGpPWpGaD
Norethindrone—ALB—Metabolism of lipids and lipoproteins—IDH1—brain cancer	8.66e-05	0.00142	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—HEY1—brain cancer	8.63e-05	0.00141	CbGpPWpGaD
Norethindrone—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—brain cancer	8.6e-05	0.00141	CbGpPWpGaD
Norethindrone—ABCB1—Integrated Pancreatic Cancer Pathway—PDGFRA—brain cancer	8.5e-05	0.00139	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—CYP2C9—brain cancer	8.47e-05	0.00139	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—DLL1—brain cancer	8.46e-05	0.00138	CbGpPWpGaD
Norethindrone—PGR—Gene Expression—NOTCH2—brain cancer	8.38e-05	0.00137	CbGpPWpGaD
Norethindrone—ABCB1—Integrated Pancreatic Cancer Pathway—PCNA—brain cancer	8.1e-05	0.00132	CbGpPWpGaD
Norethindrone—ABCB1—Allograft Rejection—VEGFA—brain cancer	7.99e-05	0.00131	CbGpPWpGaD
Norethindrone—ALB—Folate Metabolism—TP53—brain cancer	7.95e-05	0.0013	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism of lipids and lipoproteins—IDH1—brain cancer	7.77e-05	0.00127	CbGpPWpGaD
Norethindrone—ALB—Hemostasis—TRPC6—brain cancer	7.25e-05	0.00119	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—BSG—brain cancer	7.2e-05	0.00118	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—SHH—brain cancer	7.19e-05	0.00118	CbGpPWpGaD
Norethindrone—PGR—Gene Expression—SIRT1—brain cancer	7.13e-05	0.00117	CbGpPWpGaD
Norethindrone—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—brain cancer	7e-05	0.00115	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—TRPC6—brain cancer	6.94e-05	0.00113	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—PTCH1—brain cancer	6.82e-05	0.00112	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—SMO—brain cancer	6.82e-05	0.00112	CbGpPWpGaD
Norethindrone—ALB—Platelet activation, signaling and aggregation—PIK3CG—brain cancer	6.69e-05	0.00109	CbGpPWpGaD
Norethindrone—ABCB1—Integrated Pancreatic Cancer Pathway—APC—brain cancer	6.59e-05	0.00108	CbGpPWpGaD
Norethindrone—ALB—Transmembrane transport of small molecules—TRPC6—brain cancer	6.28e-05	0.00103	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—IDH1—brain cancer	6.2e-05	0.00101	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—CYP2C9—brain cancer	6.13e-05	0.001	CbGpPWpGaD
Norethindrone—PGR—Generic Transcription Pathway—MYC—brain cancer	5.8e-05	0.000949	CbGpPWpGaD
Norethindrone—ABCB1—Transmembrane transport of small molecules—TRPC6—brain cancer	5.5e-05	0.0009	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—NOTCH2—brain cancer	5.45e-05	0.000892	CbGpPWpGaD
Norethindrone—ALB—Hemostasis—VAV1—brain cancer	5.43e-05	0.000889	CbGpPWpGaD
Norethindrone—ALB—Metabolism—CYP2C9—brain cancer	5.28e-05	0.000863	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—BSG—brain cancer	5.21e-05	0.000852	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—VAV1—brain cancer	5.2e-05	0.00085	CbGpPWpGaD
Norethindrone—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—brain cancer	5.12e-05	0.000837	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—ENO2—brain cancer	4.9e-05	0.000801	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—CYP2C9—brain cancer	4.74e-05	0.000775	CbGpPWpGaD
Norethindrone—ALB—Platelet activation, signaling and aggregation—IL2—brain cancer	4.71e-05	0.000771	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—CYP2C9—brain cancer	4.62e-05	0.000756	CbGpPWpGaD
Norethindrone—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—brain cancer	4.52e-05	0.00074	CbGpPWpGaD
Norethindrone—ALB—Metabolism—BSG—brain cancer	4.49e-05	0.000734	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—IDH1—brain cancer	4.48e-05	0.000733	CbGpPWpGaD
Norethindrone—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—brain cancer	4.48e-05	0.000732	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—HES1—brain cancer	4.47e-05	0.000731	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—PDGFRA—brain cancer	4.26e-05	0.000696	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—SPP1—brain cancer	4.13e-05	0.000676	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—BSG—brain cancer	4.03e-05	0.000659	CbGpPWpGaD
Norethindrone—ALB—Platelet activation, signaling and aggregation—VEGFA—brain cancer	4e-05	0.000655	CbGpPWpGaD
Norethindrone—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—brain cancer	3.94e-05	0.000645	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—BSG—brain cancer	3.93e-05	0.000643	CbGpPWpGaD
Norethindrone—ALB—Metabolism—IDH1—brain cancer	3.86e-05	0.000631	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—IRS2—brain cancer	3.74e-05	0.000611	CbGpPWpGaD
Norethindrone—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—brain cancer	3.63e-05	0.000593	CbGpPWpGaD
Norethindrone—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—brain cancer	3.55e-05	0.00058	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—ENO2—brain cancer	3.54e-05	0.000579	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—IDH1—brain cancer	3.46e-05	0.000566	CbGpPWpGaD
Norethindrone—ALB—Hemostasis—PIK3CG—brain cancer	3.45e-05	0.000564	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—IDH1—brain cancer	3.38e-05	0.000553	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—APC—brain cancer	3.3e-05	0.00054	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—PIK3CG—brain cancer	3.3e-05	0.00054	CbGpPWpGaD
Norethindrone—ALB—Metabolism of lipids and lipoproteins—PIK3CG—brain cancer	3.14e-05	0.000514	CbGpPWpGaD
Norethindrone—ALB—Metabolism—ENO2—brain cancer	3.05e-05	0.000499	CbGpPWpGaD
Norethindrone—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—brain cancer	2.98e-05	0.000487	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—CYP2C9—brain cancer	2.85e-05	0.000466	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CG—brain cancer	2.82e-05	0.000461	CbGpPWpGaD
Norethindrone—PGR—Gene Expression—MYC—brain cancer	2.79e-05	0.000457	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—ENO2—brain cancer	2.74e-05	0.000448	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—ENO2—brain cancer	2.67e-05	0.000437	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—RELA—brain cancer	2.58e-05	0.000422	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—ERBB2—brain cancer	2.56e-05	0.000419	CbGpPWpGaD
Norethindrone—ALB—Hemostasis—IL2—brain cancer	2.43e-05	0.000397	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—BSG—brain cancer	2.42e-05	0.000396	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—IL2—brain cancer	2.32e-05	0.00038	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—CCND1—brain cancer	2.26e-05	0.00037	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—PIK3CG—brain cancer	2.25e-05	0.000368	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—CTNNB1—brain cancer	2.24e-05	0.000367	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—IDH1—brain cancer	2.08e-05	0.000341	CbGpPWpGaD
Norethindrone—ALB—Hemostasis—VEGFA—brain cancer	2.06e-05	0.000338	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—VEGFA—brain cancer	1.97e-05	0.000323	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—STAT3—brain cancer	1.95e-05	0.00032	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—MYC—brain cancer	1.82e-05	0.000297	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—EGFR—brain cancer	1.78e-05	0.000291	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—ENO2—brain cancer	1.65e-05	0.000269	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—PIK3CG—brain cancer	1.62e-05	0.000266	CbGpPWpGaD
Norethindrone—ALB—Hemostasis—TP53—brain cancer	1.56e-05	0.000255	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—TP53—brain cancer	1.49e-05	0.000244	CbGpPWpGaD
Norethindrone—ALB—Metabolism—PIK3CG—brain cancer	1.4e-05	0.000229	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—PIK3CG—brain cancer	1.26e-05	0.000205	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—PIK3CG—brain cancer	1.23e-05	0.000201	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—PIK3CG—brain cancer	7.55e-06	0.000124	CbGpPWpGaD
